Side effects: Like semaglutide, tirzepatide’s most common side effects are nausea, diarrhea, vomiting, stomach pain, and ...

Midlife weight gain is a persistent challenge for many women, but emerging research suggests hormone therapy may enhance response to glucagon-like peptide-1 (GLP-1)–based treatments.

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

Eli Lilly (NYSE:LLY) has partnered with India's Cipla to market its weight-loss medication Tirzepatide under a new brand in ...

Thousands of knockoff pens were confiscated by enforcement agents for the UK’s Medicines and Healthcare products Regulatory ...

Efficacy of tirzepatide does not differ significantly between men and women, despite sex-specific differences in obesity-related heart failure with preserved ejection fraction.

Under the agreement, Cipla will market the drug under a new brand name, Yurpeak, while Lilly continues to sell it as Mounjaro ...

A recent Northwestern Medicine study has identified novel neural circuits modulated by the diabetes and obesity-management ...

The United Kingdom's healthcare regulator on Friday said it had made the world's largest seizure of illegal weight loss ...

The first illicit production facility for weight loss medicine found in the UK has been dismantled. The discovery, in ...

Cipla and Eli Lilly India have announced an agreement to distribute a type 2 diabetes drug, tirzepatide, under the new brand ...

Britain's medicines regulator said on Friday it had made the world's largest seizure of unlicensed weight-loss medicines, ...